CBD oil trials only (2014)
In April of 2015, Gov. Fallin signed HB 2154, Katie and Cayman’s Law, which allows physicians in Oklahoma to recommend a high-CBD cannabis oil (less than 0.3% THC) to minors suffering from a severe epilepsy disorder like Lennox-Gastaut Syndrome or Dravet Syndrome. In 2016, the state adopted HB 2835, which expanded legal protections to patients of all ages and added several new qualifying conditions including “spasticity due to multiple sclerosis or due to paraplegia, intractable nausea and vomiting, and appetite stimulation with chronic wasting diseases.”
There are certain qualifying conditions for medical marijuana approval.
- Must be under the age of 18 suffering from:
- Lennox-Gastaut syndrome
- Dravet syndrome
- Severe myoclonic epilepsy of infancy
- Any form of refractory epilepsy not treatable by traditional medical therapies
Cannabis Possession Limit:
In any case, CBD oil may not contain more than 0.3% THC.
Manufacturing/ProcessingOnly by FDA approval
The CBD oil for the trial must be obtained from a provider approved by the U.S. Food and Drug Administration (“FDA”) who has manufactured and tested the oil in a facility approved by the FDA.